WebAbout Highlight Therapeutics Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. Pipeline Unlocking the potential of IO WebMar 22, 2024 · Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders Mar 22, 2024 (PRNewswire via...
75+ Active Companies working to develop 75+ Pipeline Therapies
WebMar 22, 2024 · Biohaven ( BHVN) was up more than 2% after saying it has acquired a license from Hangzhou Highlightll Pharmaceutical to develop BHV-8000, a treatment candidate for immune-mediated brain disorders. WebA qualified treating physician for any expanded access request must be identified and the physician must agree to comply with all applicable Highlightll (USA) Pharma and local regulatory requirements, including safety reporting, adverse event collection and long-term follow-up consistent with local health authority requirements. dog surrender houston texas
BioCentury - Hangzhou Highlightll: Twice the target, hold the tox
WebMar 22, 2024 · Biohaven ( NYSE: BHVN) said it acquired global rights, excluding China regions, for BHV-8000 to treat brain disorders from Hangzhou Highlightll Pharmaceutical. Highlightll will get $10M cash... WebNov 24, 2024 · Brief Summary: This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in … WebJul 3, 2024 · Hangzhou Highlightll Pharmaceutical Co. Ltd. announced Thursday that it raised more than RMB210 million ($30 million) across its series B and B+ rounds, with Hankang Capital leading the series B+... fairfax banks \\u0026 credit unions